- Trial phase
- Phase 3
- Time to market
- At least 4-5 years, assuming Phase 3 success and regulatory filing around 2030-2031
- Why 2/10
- No hard dated catalyst exists within the next ~12 months: the Phase 3 INVEST-HD trial (NCT07326709) began enrolling in March 2026, targets 770 patients, and has an estimated primary completion date of April 2030. For Novartis, a $200B+ diversified pharma with dozens of marketed drugs, votoplam is a small pipeline component, so even a distant readout would not be a company-defining event.
The next hard catalyst is the Phase 3 INVEST-HD topline readout, expected around 2030, roughly 3+ years away. For Novartis, a $200B+ diversified pharma, votoplam is one of many pipeline assets; the readout is too distant and too small a concentration to drive a major share-price move. Watch for interim updates at medical conferences (e.g., 2027-2028) and any regulatory pathway clarity (accelerated approval discussions), but near-term stock movement from this drug alone is unlikely.
Price Chart
Executive Summary
Votoplam (formerly PTC518/HTT227) is an investigational oral small-molecule HTT splicing modifier being developed by Novartis for Huntington's disease (HD), a fatal genetic neurodegenerative disorder with no approved disease-modifying therapies. In December 2024, Novartis paid PTC Therapeutics $1B upfront (up to $2.9B total) to license the program. Phase 2 PIVOT-HD data showed statistically significant huntingtin protein reduction (p<0.0001), and 24-month extension data reported in April 2026 showed 52% slowing of disease progression at the 10mg dose versus a natural-history cohort. The Phase 3 INVEST-HD trial (NCT07326709) began enrolling 770 patients in March 2026, with a primary completion date estimated in April 2030. Roche's competing HD programs (tominersen, RG6496) were discontinued in July 2026, narrowing the competitive field. For Novartis, votoplam is a small pipeline asset within a $200B+ diversified pharma; the distant readout timeline and low concentration mean it is unlikely to be a near-term stock driver.
How It Works
Votoplam is a daily pill that works by modifying how the HTT gene's instructions are spliced, reducing the production of the toxic huntingtin protein that causes Huntington's disease. It is designed to slow or stop disease progression rather than just treat symptoms.
Trial Status
The Phase 3 INVEST-HD trial (NCT07326709) began enrolling in March 2026, is currently recruiting at 117 sites across 27 countries, and targets 770 participants with early symptomatic HD. Estimated primary completion is April 2030. Phase 2 PIVOT-HD met its primary endpoint, and a 24-month interim analysis of the long-term extension showed dose-dependent slowing of disease progression.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 INVEST-HD topline readout (estimated ~2030), the pivotal efficacy/safety data
- Potential interim data presentations at medical conferences (e.g., 2027-2028)
- Any FDA discussions on accelerated approval pathway (no public updates as of Oct 2026)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report